---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029071"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:21:40.820406+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q4 revenue $121.6M (+50% YoY); full year net income $35.5M; 2025 guidance $530-552M

## Summary
- Q4 revenue $121.6M (+50% YoY); net income $6.9M ($0.19 EPS); full year revenue $441.5M (+83% YoY).
- Full year net income $35.5M ($1.01 EPS) vs net loss $25.0M in 2023; 2025 revenue guidance $530-552M (20-25% growth).
- U.S. OCS cases 3,715 in 2024 (+58% YoY); overall OCS market share 20.9% (up from 13.8% in 2023).
- Independent review found no misconduct after short report allegations; submitted response to FDA Citizen Petition.
- Gross margin 59.4% full year, down from 63.8% due to higher service revenue mix; cash $336.7M.

## SEC filing metadata
- accession: 0000950170-25-029071
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017025029071/0000950170-25-029071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017025029071/tmdx-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029071
- JSON: https://secwatch.observer/filing/0000950170-25-029071.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.